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Abstract.  The CD44 cell surface glycoprotein is ex- 
pressed on a broad range of different tissues as multi- 
ple isoforms containing  from one to ten alternatively 
spliced exons vl-vl0 inserted within the extracellular 
domain.  Differential glycosylation generates still 
further variability, yielding both N- and O-glycan- 
modified forms of CD44 in addition to proteoglycan- 
like variants containing chondroitin  sulphate and 
heparan  sulphate.  These high molecular mass proteo- 
glycan-like variants,  previously identified in lympho- 
cytes, melanomas,  and keratinocytes have been impli- 
cated in cell-matrix adhesion,  cell motility, and 
invasiveness.  More recently, monocyte CD44 mole- 
cules presumed to carry glycosaminoglycan chains 
were shown to bind the chemokine MIP-1/~ (Tanaka, 
Y., D.  H. Adams,  S.  Hubscher, H. Hirano,  U.  Sieben- 
list, and S.  Shaw.  1993.  Nature  (Lond.).  361:79-82.) 
raising the intriguing  possibility that proteoglycan-like 
CD44 variants might play a role in regulating inflam- 
matory responses. 
Here we have investigated the molecular identity of 
these proteoglycan-like CD44 variants by generating a 
panel of recombinant CD44 isoforms using a novel 
cassette cloning strategy.  We show that both chondroi- 
tin and heparan sulphate modifications are associated 
specifically with isoforms (CD44v3-1o and CD44v3,8-1o) 
containing the v3 alternative exon which encodes a 
consensus motif SGXG for GAG addition.  Other iso- 
forms (CD44v10, CD44vs-10, CD44v7-1o, and CD44,~-~o) 
are shown to lack these GAG chains but to carry ex- 
tensive O-glycan modifications, most likely within the 
mucin-like alternative exon inserts.  We also demon- 
strate that the majority of endogenous GAG-modified 
CD44 isoforms present in epithelial cells constitute v3 
isoforms thus establishing that in these cells the 
majority of proteoglycan-like CD44 variants are gener- 
ated by alternative splicing.  Finally we present evi- 
dence using transfected B lymphoma cells that the 
GAG-modified CD44 isoforms CD44v3-10 and 
CD44~3,8-~0, unlike CD44H, bind only weakly to 
hyaluronan.  Together with the demonstration  in the ac- 
companying paper (Bennett, K.,  D.  G.  Jackson, J.  C. 
Simon,  E.  Tanczos,  R. Peach,  B.  Modrell,  I. 
Stamenkovic, G. Plowman, and A. Aruffo.  1995. J. 
Cell Biol. 128:687-698.), that CD44 molecules con- 
taining the v3 exon bind growth factors, these results 
highlight a new and potentially important  role for 
CIM4 alternative splicing in the control of cell-surface 
proteoglycan expression. 
T 
HE  CD44  cell  surface  glycoprotein is  broadly  ex- 
pressed  by  cells  of  haemopoietic,  epithelial,  and 
mesothelial origin where it is thought to mediate a vari- 
ety of functions including cell-extracellular  matrix binding, 
leucocyte-endothelial  transmigration,  and lymphocyte acti- 
vation (for review see Lesley et al., 1994). Furthermore, ex- 
perimental evidence links CD44 with a possible role both in 
tumour metastasis (Gunthert  et al., 1991) and in the control 
of cell  migration  during  normal  embryonic development 
(Wheatley  et al.,  1993). 
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One of the most striking features of the CD44 glycoprotein 
is the extent of molecular weight heterogeneity that is appar- 
ent  when  CD44  antigens  are  immunoprecipitated  from 
different cell types (Omary et al.,  1988; Pals et al.,  1989; 
Picker et al., 1989; Kansas et al., 1989; Brown et al., 1991; 
Kennel et al., 1993). Originally ascribed to posttranslational 
modification,  this heterogeneity  is now recognized  to arise 
mainly from posttranscriptional  RNA splicing (Dougherty et 
al., 1991; Brown et al., 1991; Hofmann et al., 1991; Jackson 
et al., 1992; He et al., 1992) during which up to ten alterna- 
tive exons (vl-vl0) may be inserted in tandem within a region 
of the mRNA that codes for the membrane-proximal  portion 
of the extracellular  domain (Screaton  et al.,  1992,  1993). 
The alternatively spliced CD44 isoforms which range in size 
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sion to cells of epithelial origin whereas an 80-90 kD form 
(termed the haemopoietic form, CD44H) which lacks all ten 
alternative exons predominates in most cell types (for review 
see Lesley et al.,  1994). 
Although the precise functions of the alternatively spliced 
CD44 variants (vCD44) I are unknown, it is recognized that 
CD44H  acts  as  the  major  receptor on  lymphocytes and 
fibroblasts for hyaluronan (Culty et al.,  1990; Lesley et al., 
1990; Aruffo et al.,  1990), an extracellular-matrix glycos- 
aminoglycan that is highly abundant in the interstitial spaces 
of mesothelial tissues where it is thought to play a key role 
in the control of cell migration.  The binding  site for hy- 
aluronan is in fact present in all CD44 isoforms where it is 
located within  the  invariant,  NH2-terminal portion of the 
extracellular domain that shares homology with the hyaluro- 
nan-binding domains of the tissue-matrix proteoglycans ag- 
grecan, versican, and link protein (Stamenkovic et al., 1989; 
Goldstein et al.,  1989). In common with these large matrix 
proteoglycans, all forms of CD44 also contain a highly gly- 
cosylated mucin-like domain rich in serine and threonine 
residues,  which  connects the  hyaluronan-binding  domain 
with  the  plasma  membrane.  This  invariant  membrane- 
proximal  domain  contains  four  serine-glycine motifs  for 
potential  covalent  modification  with  glycosaminoglycans 
(Bourdon et al.,  1985), and it has been assumed that one or 
more of these is the site of attachment for chondroitin sul- 
phate and heparan sulphate chains in high molecular weight 
proteoglycan-like forms of CD44. 
Recent  reports  have  suggested  important  functions  for 
these  proteoglycan-like  CD44  molecules.  For  example, 
chondroitin sulphate-modified forms of CD44  in  murine 
melanoma cells were shown to regulate motility and inva- 
siveness in collagen gels (Faassen et al.,  1992,  1993) while 
another chondroitin sulphate-modified variant from human 
lymphocytes was shown to bind the extracellular matrix pro- 
teins fibronectin and laminin (Jalkanen and Jalkanen, 1992). 
Furthermore CD44 molecules isolated from human mono- 
cytes were recently shown to sequester the glycosaminogly- 
can (GAG)-binding monokine MIP-1/~ (Tanaka et al., 1993), 
raising the possibility that proteoglycan-like forms of CD44 
might function in the binding and presentation of growth 
factors. 
In this report we describe the results of experiments de- 
signed to characterize these proteoglycan forms of CD44 
and to determine the nature of their ligands.  Using a novel 
cassette cloning method,  we have constructed a  panel of 
recombinant  CD44  alternative  splice  variants  containing 
combinations of exons v3 to vl0 which have been stably 
transfected into the CD44  -~ B lymphoma Namalwa.  First, 
we  show  that  the  major  GAG-modified  CD44  isoforms 
within this panel and in two other epithelial cell lines are in 
fact alternative splice variants containing the v3 exon. This 
demonstrates for the first time that alternative splicing plays 
a  major  role  in  the  generation of proteoglycan forms of 
CD44.  The ability of these GAG-modified forms to bind 
growth factors is demonstrated in the accompanying paper 
(Bennett et al.,  1994). Second, we identify O-glycosylation 
as the major modification of alternative exons other than v3, 
1. Abbreviations used in this paper:  vCD44,  spliced CD44 variant; GAG, 
glycosaminoglycan. 
and third, we describe ligand-binding studies which demon- 
strate that GAG-modified CD44 isoforms, when expressed 
in a B-lymphoma cell line, have greatly reduced affinities for 
hyaluronan relative to CD44H. Finally, we discuss the possi- 
ble presence of a weak interaction between CD44 v3 con- 
taining isoforms and fibronectin and laminin. 
Materials and Methods 
Cell Lines and Monoclonal Antibodies 
The squamous cell lung carcinoma "Hotz" was kindly provided by Dr.  P. 
Groscurth (Zurich,  Switzerland),  the adenovirus  12-SV40 hybrid virus- 
transformed bronchial epithelial line BEAS-2B was provided by Dr. C. C. 
Harris, National Cancer Institute (Bethesda, MD); and the cervical carci- 
noma HeLa, the vulval carcinoma A-431, the colon adenocarcinoma HT29, 
and the mammary adenocarcinomas MCF-7 and MCF-10 were generously 
donated by Dr.  Ken Smyth (ICRF Molecular Oncology Unit, IMM, Ox- 
ford,  UK).  All cell lines were grown in RPMI-1640  supplemented with 
10% FCS. 
The CD44 framework antibody E10.44.2 (Dalchau et al.,  1980) was a 
kind gift from Dr. Maria Dalchau and was purified from hybridoma culture 
supernatant by affinity chromatography on columns of protein A-Sepharose 
(Pharmacia,  Sweden).  The  mouse  monoclonal  antibody  3G5  (subclass 
IgG2a) specific for alternatively spliced isoforms of human CIM4 contain- 
ing the alternative v3 exon was generated as described previously (Fox et 
al.,  1994). FI'IC-conjugated goat antibodies to mouse IgG and the isotype 
control mouse myeloma immunoglobulin UPC-10 (IgG2a Kappa) were ob- 
tained from the Sigma Chem.  Co.  (Poole,  Dorset,  UK). 
Radiochemicals 
Nat25I (17 mCi/ttg), Na235SO4 (100 mCi/mmol), and Na251CrO4 (250-550 
mCi/mg Cr) were obtained from Amersham International Public United 
Company (Amersham, UK). 
Preparation of "Mini-Libraries" Encoding Variably 
Spliced Regions  from vCD44 cDNAs 
DNA  sequences  constituting  most  of  the  extraceilular  domain-coding 
regions from alternatively spliced CD44 isoforms were generated by PCR 
using eDNA from the squamous cell lung carcinoma Hotz and the normal 
bronchial epithelial line BEAS-2B using the primers AMP1Eco (5' CCG- 
GAATTCCCAGTATGACACATAT'IV~ 3') and AMP3Eco (5' CCGGAATT 
CCTTCGTGTGTGG GTAATG 3') located in exons 3 and 15 (vl0) of CIM4 
as described previously (Jackson et al., 1992, 1994). Products were purified 
on glass beads (Gene Clean, Stratech, UK), digested with EcoRI (50 U, 
37°C),  and cloned into EcoRI cut M13mpl8 generating mini-libraries of 
vCIM4 clones representing CD44v10,  CD44vs-10, CD44vT-t0, CD44v6-10, 
CD44v3-t0 and CD44v3~-i0 identified by DNA sequencing using the di- 
deoxynucleotide "chain termination" method (Sanger et al.,  1977) with T'/ 
DNA polymerase and 7-deaza-dGTP. 
Preparation of CD44 lsoform Constructs and Stable 
Transfection of  Namalwa Cells 
Full-length CIM4 constructs for stable expression were prepared by a novel 
cassette cloning strategy in which the variably spliced regions derived from 
the RT-PCR mini-libraries described above were inserted into a CD44~1o 
clone containing unique BglII and NarI sites introduced by site-directed 
mutagenesis. In the following description, all exon numbering follows the 
convention shown in Fig.  1 B. 
Production  of  Variably Spliced  CD44  Fragraents  with  Compatible 
Ends  for  Cassette  Cloning.  DNA  clones  representing  the  isoforms 
CD44vS-to,  CDa4v7-10,  CD44v6-10,  CD44v3,S-lO,  and  CD44v3-1o  were 
amplified  from  mini-libraries of epithelial cell  vCD44  DNA  fragments 
using the primers NRW77BglII and NRW78NarI (see below for sequences) 
in reactions (50 #1) consisting of template DNA (100 rig), primers (0.2 ItM), 
and deoxynucleotide triphosphates (1 mM), catalyzed by the addition of 1 U 
Pyrococcusfuriosus  DNA polymerase (Strategene Ltd., Cambridge, UK). 
The cycle parameters were 94"C, 1 min; 60°C, 3 min; and 72°C,  ! min for 
30 cycles. Products were then digested with BgllI and Narl (37°C) to gener- 
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Figure 1. Construction of a panel  of full-length  cDNAs encoding 
alternatively spliced human CIM4  isoforms.  A  shows the strategy 
employed for cloning full-length  vCD44 constructs by PCR from 
CD44 eDNA mini-libraries  and  insertion  into the  mutagenized 
plasmid  construct  pBCk~-CD44~j0  ~mm=I* (see Materials  and Meth- 
ods). B shows a diagrammatic representation  of the final panel of 
CIM4  isoform  constructs  including  the  independently  derived 
CD44H  (see  Materials  and  Methods)  used  to transfect  Namalwa 
cells.  The positions  of motifs  for putative  modification  with  gly- 
cosaminoglycans  are  indicated  with the symbols  (?). 
ate  the  appropriate  cohesive  ends  for  ligation  with  the  cassette  vector 
pBCkS-CD44v10  asl/Nar** (Fig.  1 A). 
Construction of the CD44vlo Cassette  Cloning  Vector by Site-directed 
Mutagenesis.  The full-length CD44vm cDNA described in Jackson et al. 
(1992)  was  subcloned  from pCDM8  into the pBC  ks-  phagemid  (Strata- 
gene, UK) for single stranded DNA preparation with R408 helper phage 
after transformation of E.  coli XL-I blue.  Using oligonucleotide-directed 
mutagenesis new restriction sites for BgiII and NarI/KasI were introduced, 
respectively,  in exon  5  (nt 673-676  in  Stamenkovic  et  al.  [1989];  GA- 
GC-"ATCT) and exon 15 (AAGAA~C_~GCC) using the primers NRW77- 
BgiII  (AGTGAAagatctAGCACTTCAGGAGG)  and  NRW78Narl  (TGG- 
GTCTCggcgccCACCTGTGACATCATT).  The  integrity  of  the  resulting 
construct pBCkS-CD44v10  Bsl/Nar** (Fig.  1 A) was confirmed by DNA se- 
quencing on both strands.  For cassette cloning,  the vector was digested 
overnight with BglII and NarI before ligation with the appropriate RT-PCR 
products containing compatible ends described above. 
Expression  of recombinant  CD44 isoforms.  Full-length constructs in 
the cassette vector pBCkS-CD44v 10  agl/Nar** Were checked by DNA sequenc- 
ing and subeloned into the HindIII/NotI cloning site of the eukaryotic ex- 
pression vector pRcCMV (InVitrogen, San Diego,  CA) for transfection of 
the CD44  TM B cell lymphoma Namalwa by electroporation (960 #F, 750 
Wcm).  The CD44H  expression construct was prepared by subeloning an 
existing full-length human CIM4H eDNA clone (Stamenkovic et al.,  1989) 
into the NotI-HindIII site of pRcCMV.  Stable transfectants were selected 
first for growth in the presence of G418 (2.5 mg/ml; GIBCO BRL, UK) and 
second, for cell surface CD44 expression using anti-mouse Is-coupled Dy- 
nabeads (DYNAL,  Oslo,  Norway)  coated with the CD44mAb  E10.44.2 
according to the manufacturer's instructions. The resulting cell lines were 
analyzed periodically for surface expression by staining with E10.44.2 or 
with phycoerythrin-conjugated A3D8 mAb (Sigma, UK) followed by quan- 
titative FACScan  ® analysis as described below. 
Immunofluorescent Antibody Staining and 
Flow Cytometry 
Cells (5  ×  105) were washed once in PBS,  containing 1% human serum 
and 0.1%  NaN3  before incubation (20 rain,  4°C)  with  100 #l of CD44 
mAbs (10 #g/ml). After washing in PBS, cells were reincubated (30 rain, 
4°C)  with  100  #l  fluorescein-conjugated  goat  anti-mouse  IgG  (Sigma 
Chem. Co., UK) before recentrifugation and resuspension in PBS contain- 
ing 2% (wt/vol) formaldehyde fixative. Stained cells were analyzed either 
by flow cytometry on a FACScan  ® or by microscopy using a Zeiss fluores- 
cence microscope with automatic camera (Becton-Dickinson Immunocy- 
tometry  Sys.,  Mountain View,  CA). 
Cell Surface Iodination, Biosynthetic Labeling with 
35(S04)  2- and Immunoprecipitation 
Cell surface radioiodination was carded out by the lactoperoxidase/glucose 
oxidase catalyzed reaction as described previously (Jackson et al.,  1992). 
In the case of adherent cells these were first detached by incubation (37°C, 
30 min) in PBS, pH 7.5,  1 mM  EDTA.  Thereafter all cell types (0.5-1  x 
107) were resuspended in PBS, pH 7.5, 5 mM glucose, and incubated (20 
rain,  room  temperature)  with  400  mU  bovine  milk  lactoperoxidase 
(E.C.I.ll.I.7,  Sigma,  UK) and 240 mU AspergiUus niger glucose oxidase 
(EC  1.1.3.4,  Sigma, UK) in the presence of 0.5 mCi Na~25I. Labeled cells 
were then washed three times (PBS, 1 mM NaI) to remove free t25I- before 
solubilization in detergent (see below). 
For biosynthetic incorporation of 35SO42- cells were incubated (37°C, 
6-24  h)  in  sulphate  free  DMEM,  10%  FCS  containing  100  #Ci/ml 
Na235SO4 (Amersham,  UK).  Residual unincorporated  radiolabel was re- 
moved by washing labeled cells in PBS,  pH 7.5. 
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ml Tris-HCI (20 mM) pH 7.5, containing Triton X-100 (1% wt/vol),  NaCI 
(150 mM),  EDTA  (1  mM),  phenylmethanesulphonylfluoride  (0.5  mM), 
leupeptin (50 t*g/ml), and iodoacetamide  (5 mM) followed by centrifugation 
(9,000 g, 5 rain) to remove particulate material. The resulting snpernatants 
were precleared twice by end over end mixing with 100 #110% wt/vol Pan- 
sorbin (Calbiochem-Novabiochem.  Corp., LaJolla, CA) followed by 100 #1 
50% protein A-Sepharose CL-4B/mouse IgG (1 h, 5°C). After centrifuga- 
tion,  (9,000  g)  supernatants were  decanted and mixed  (1  h,  5°C)  with 
specific antibody (either E10.44.2 or 3G5,  10/~g/ml)  before the addition 
of 50 #1  1:1 (vol/vol) protein A-Sepharose CL-4B.  Immobilized immune 
complexes were recovered by centrifugation and washed with TEN buffer 
(20 mM Tris-HCI, pH 7.5, 100 mM NaCI,  1 mM EDTA) containing Triton 
X-100 (0.1%) followed by TEN buffer without Triton X-100 before enzy- 
matic deglycosylation  or SDS-PAGE. 
Removal of O-linked Sugars, N-linked Sugars, 
and Glycosaminoglycans 
CD44 isoforms  immunoprecipitated from surface  ~2SI-labeled cells were 
treated with either N-glycosidase  F  (12.5  U/ml Flavobacterium menin- 
gosepticum enzyme,  EC 3.2.2.18,  Genzyme, UK) in 0.1 M Na phosphate 
buffer pH 8.6, or with neuraminidase (250 mU/ml Vibrio cholerae enzyme, 
EC 3.2.1.18, Calbiochem-Novabiochem  Corp.) followed by O-glycosidase 
(5  mU/ml Diplococcus  pneumoniae  enzyme,  EC  3.2.1.97, Boehringer 
Mannheim, UK) in 40 mM Tris-acetate  buffer, pH 6.0, containing calcium 
acetate,  for the removal of N- and O-linked carbohydrates,  respectively. In 
addition, immunoprecipitated  125I- and 35SO42- labeled  CD44  isoforms 
were treated with either chondroitin ABC lyase (0.5 U/ml Proteus vulgaris 
enzyme, EC 4.2.2.4, Boehringer Mannheim, Lewes, East Sussex, UK) in 
40 mM Tris acetate buffer, pH 8.0, or with heparitinase (0.1 U/rnl Flavobac- 
terium heparinum enzyme,  EC 4.2.2.8, Seikagaku Corporation, Tokyo, Ja- 
pan) in PBS, pH 7.0. Deglycosylated proteins were recovered by precipita- 
tion with 10% (wt/vol) TCA and analyzed on 7.5% acrylamide SDS-PAGE 
gels followed by autoradiography. 
Adhesion Assays 
Transfected  Namalwa  cells labeled with 51Cr (typically  2  ×  106 cells in 
100 #1 Na2(SICrO3), 1 h, 37°C) were assayed for binding to matrix compo- 
nents in 24-well tissue culture or 96-well microtitre plates. Plates were pre- 
pared by coating either human fibronectin (0.1 mg/ml, Calbiochem, lot No. 
536892),  human laminin (0.1 mg/ml, Calbiochem, lot Nos.  244791 and 
B09306)  or hyaluronan  (5 mg/ml, Sigma) overnight in PBS, pH 7.5, fol- 
lowed by blocking (24 h, room temperature) with either heat-denatured  bo- 
vine serum albumin or with desialated human fetuin (Sigma,  1 mg/rnl). For 
binding assays, cells were added either to 96-well plates (104 in 50/zl PBS, 
pH 7.5) or to 24-well plates (5 ×  104 in 250/~1 PBS, pH 7.5) and incubated 
for 60 min at 250C or in some experiments at 5°C. In competitive-binding 
experiments,  cells were preincubated (15 rain, 5°C) with either BSA, chon- 
droitin sulphate,  heparin (Sigma,  UK),  soluble fibronectin (Calbiochem- 
Novabiochem Corp.), or with the 40-kD ~ chymotryptic  heparin-binding 
fragment of fibronectin  (Gibco, UK) before the adhesion assay. For the mea- 
surement of hyaluronan binding, non-adherent cells were removed during 
three washes of the plates  (500/~l/wash) by pipeuing and gentle tapping. 
In the case of fibronectin and laminin binding, the incubation was preceded 
by a brief centrifugation  step (500 g, 5 s) and non-adherent  cells were care- 
fully removed at the end of the assay by gentle rinsing (3×  100/~1 PBS) 
with a multichannel micropipette.  In each case adherent cells were lysed 
by the addition of 1% Triton 3[-100 and samples of lysate were counted for 
radioactivity  using an LKB 1205 Beta plate Liquid scintillation  spectrom- 
eter. Results were scored for both the total number of cells bound in each 
well  (normalized for differences  in the amount of S~Cr incorporated by 
each transfectant)  and for the percentage of cells bound in each well (cpm 
bound/cpm added  ×  100). 
Results 
To study the functions of individual CD44 splice variants, 
we developed a  simple and rapid strategy by which these 
could be generated without having to resort to conventional 
cDNA library screening procedures. The two basic steps in 
this technique which we have termed "cassette cloning" (Fig. 
1 A) consisted of (a) PCR-amplification of the alternatively 
spliced regions from mini-libraries containing variant CD44 
cDNAs, and (b) insertion of  the products as cassettes into the 
homologous site of a mutagenized CD44 cDNA clone. The 
resulting hybrid cDNA clones (Fig.  1 B) were then stably 
transfected into the CD44  -V° B lymphoma Namalwa. 
The two stages of the cassette cloning procedure are de- 
scribed in more detail in the following section. 
Construction and Stable Expression of a Panel of 
Full-Length CD44 Isoforms 
We first amplified DNA  fragments  encoding the  alterna- 
tively  spliced  regions  from vCD44  isoforms  from  mini- 
libraries of CD44 cDNAs prepared from the bronchial epi- 
thelial  cell  lines  Hotz  and  BEAS-2B  using  the  primers 
NRW77BglII and NRW78NarI located within exons 5 and 
15  (vl0),  yielding products  identified  by  DNA  sequenc- 
ing  as  CD44v10,  CD44vT-to,  CD44v6-10,  CD44v3,s-10, and 
CD44~3-t0. These eDNA mini-libraries were initially gener- 
ated by RT-PCR of total RNA using the primers AMP1Eco 
and AMP3Eco located within exons 3 and  15 (vl0) as de- 
scribed in our original paper (Jackson et al.,  1992)  and in 
a more recent publication (Jackson et al.,  1994). 
We  next  mutated  a  full-length  CD44~o  cDNA  in  the 
phagemid pBC  ks- (Fig.  1 A), introducing unique BgllI and 
NarI restriction sites to allow homologous insertion of the 
PCR-amplified vCD44  fragments described above.  These 
new  sites  were  created by  altering  the  native  sequences 
AGGAGC-'AGATCT (nt  671-676  in  Stamenkovic et  al., 
1989)  and  GAAGAA--~GCGCC  located  within  CD44 
exons 5  and  15 (vl0),  respectively, choosing substitutions 
that exploited codon degeneracy and thus ensured that the 
final constructs contained no changes in the translated amino 
acid sequence. 
After subcloning  into the  eukaryotic expression vector 
pRcCMV,  the panel of CD44 isoforms shown in Fig.  1 B 
was  stably transfected into the CD44 -~ B  cell lymphoma 
Namalwa yielding cell lines in which the mean level of sur- 
face expression was within 40% as determined by quantita- 
tive immunofluorescent antibody staining (Fig. 2). 
Alternatively Spliced CD44 lsoforms Are 
Heavily O-Glycosylated 
Analysis of the full panel of recombinant CD44 isoforms in 
Namalwa cells by surface t2q-labeling and immunoprecipi- 
tation (Fig. 3) revealed a single discrete band as expected for 
CD44H,  CD44v10, CD44vs-io,  CD44~7-to, and  CD44v6-to. 
However, both CD44v3,8-10 and CD44v3-10 migrated as in- 
distinct high molecular weight smears, extending as far as 
the stacking gel in each case (see next section for full discus- 
sion).  In  comparison  with  CD44H,  each  CD44  isoform 
migrated  with  an  apparent molecular mass  that  was  dis- 
proportional to the size of the variable exon insert. For exam- 
ple the CD44v6-10 variant migrated with an apparent mo- 
lecular mass of 160 kD, some 70 kD larger than CD44H (90 
kD), despite the fact that the calculated mass of the v6-10 
polypeptide insert is only 21.8 kD.  In view of the fact that 
all ten human CD44 alternative exons encode polypeptide 
units  that  are  rich  in  both  serine  and  threonine  residues 
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bly transfected with CD44 isoforms. Namalwa cells stably trans- 
fected with cDNAs encoding the CD44  isoforms or control un- 
transfected Namalwa cells (CON) were assessed for surface CD44 
expression by indirect immunofluorescent antibody staining with 
the pan CD44 mAb E10.44.2 and quantitative FACS analysis as de- 
scribed under Materials and Methods. The values indicated are the 
mean fluorescent intensity (linear scale on Y-axis) for each cell 
population  derived  using the  LYSYS II data  analysis program 
(Becton-Dickinson Immunocytometry Sys.). 
Figure 3.  SDS-PAGE analysis of recombinant human CD44 iso- 
forms expressed in Namalwa cells. Namalwa cells stably trans- 
fected with each of the human CD44 isoforms shown were surface 
labeled with t2sI before immunoprecipitation with the pan CD44 
mAb E10.44.2  and electrophoresis on a 7.5% acrylamide SDS- 
PAGE  gel  followed by  autoradiography  as  described  under 
Materials and Methods. The molecular weight calibration marker 
proteins were/3-galactosidase (205 kD), myosin (160 kD), phos- 
phorylase b (116 kD), bovine serum albumin (67 KD), and ovalbu- 
min (45 kD). 
(mean 30%; Screaton et al., 1993), we considered the possi- 
bility that the anomalous migration reflected heavy O-glyco- 
sylation. AS shown in Fig. 4, treatment of tz~I-labeled CD44 
isoforms with neuraminidase and O-glycanase resulted in a 
dramatic decrease in apparent molecular mass in each case 
(e.g.,  CD44v~0, 49  kD;  CD44v8-10, 32  kD;  CD44v7-10, 50 
kD; CD44v6-t0, 35 kD: CD44v3.s-lo, 30 kD) compared with 
CD44H (16 kD).  Hence the alternatively spliced isoforms 
must carry substantial  amounts of O-linked glycans addi- 
tional to the 4-50-glycan chains  identified previously in 
CD44H (Lokeshwar and Bourguignon, 1991) and these pre- 
sumably are attached to the variably spliced portions of the 
membrane-proximal domain. The alteration in mobility pro- 
duced  by  digesting  the  t25I-labeled  CD44  isoforms  with 
neuraminidase alone together with the fact that cleavage of 
O-glycans  did  not  procede  without  prior  neuraminidase 
treatment (data not shown and Lokeshwar and Bourguignon, 
1991) indicates that some or all of the O-linked sugars termi- 
nate with sialic acid. 
We also considered the possibility that the vCD44 iso- 
forms might carry additional N-linked glycans. In contrast 
to O-glycosylation, only two CD44 alternative exons v5 and 
vl0 contain the motif NXS/T for N-glycosylation (Screaton 
et al.,  1992) although six such motifs are located within in- 
variant regions of the extracellular domain common to all 
CD44 variants (Stamenkovic et al.,  1989; Goldstein et al., 
1989). Treatment with N-glycanase (Fig. 4 B) produced the 
same drop in molecular mass in each of the variant CD44 
isoforms as that observed for CD44H (*20 kD) indicating 
that  the  alternatively  spliced  regions  do  not  carry  large 
amounts of additional N-glycans. 
Recombinant CD44 Isoforms Containing 
the v3 Exon Are Heparan Sulphate and Chondroitin 
Sulphate Proteoglycans 
In  contrast  to  the  CD44  isoforms  discussed  above,  ~25I- 
labeled  CD44v3-10 and  CD44v3.8-~0 expressed in  Namalwa 
cells migrated as a high molecular weight smear close to the 
top of the resolving gel during SDS-PAGE- a common fea- 
ture of proteins that are covalently modified with sulphated 
glycosaminoglycans. Since these two isoforms were the only 
ones to contain the CIM4  v3 exon that encodes the con- 
sensus  motif SGSG  for  GAG  addition  (Bourdon  et  al., 
1987), it seemed likely to us that the high molecular weight 
smear might reflect specific modification of the v3 insert by 
GAG chains such as  chondroitin sulphate or heparan sul- 
phate.  As  an  initial  test  of this  hypothesis,  ~2~I-labeled 
CD44v3-10 and v3,8-10 were digested with chondroitin ABC 
lyase followed by SDS-PAGE analysis to detect GAG removal 
as a decrease in the charge to mass ratio. The results of this 
analysis (Fig. 4 b) showed that chondroitinase treatment in- 
deed reduced the amount of smearing associated with the 
v3,8-10 and v3-10 variants but had no effect on the mobil- 
ity of either CIM4H,  CD44~0,  CD44~s-~0, CO44vT-10,  or 
CD44~6-10. Treatment with heparitinase (not shown) yielded 
similar results. Hence the smearing associated with the v3- 
containing isoforms is due to the presence of both heparan 
and chondroitin sulphate modifications. 
The presence of covalently linked GAG chains was further 
confirmed after biosynthetic incorporation of 3sSO42-. As 
shown in Fig. 5, CD44v3.s-,0 incorporated 35SO,2- into GAG 
chains that were sensitive to digestion by heparitinase and to 
Jackson et al. CD44v3 Variants  Are Heparan Sulphate Proteoglycans  677 Figure 4.  Enzymatic removal of O-linked sugars,  N-linked sugars,  and chondroitin sulphate.  Recombinant human  CD44 isoforms were 
immunoprecipitated from surface 125I-labeled Namalwa cells using the pan CD44 mAb E10.44.2 before treatment with different glycosi- 
dases as described under Materials and Methods. In the experiment shown in a, proteins were incubated with either neuraminidase alone 
(NANAse) or with neuraminidase followed by O-glycanase (NANAse/O-glycanase); the migration positions of the undigested proteins are 
indicated to the left of the gel in each case. In b, proteins were incubated with either N-glycanase or chondroitin ABC lyase as indicated. 
Samples were in each case electrophoresed on 7.5 % SDS-PAGE gels for autoradiography.  The molecular mass calibration markers were 
the same as those shown in Fig.  3. 
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were obtained with CD44~3-~o (not shown). The difficulty in 
detecting chondroitin sulphate by 35SO42- labeling despite 
its  clear  detection by  125I-labeling indicates  either  a  low 
turnover rate for the chondroitin sulphate chains of CD44 in 
Namalwa cells or a low level of sulphation. In this respect, 
it is interesting to note that O-sulphation is a feature of chon- 
droitin chains whereas both O- and N-sulphation occurs dur- 
ing the biosynthesis of heparan chains (Kjellen and Lindahl, 
1991). In contrast to the v3 variants, the two other variants 
analyzed,  CD44H  and  CD44~7-10, incorporated  much 
smaller  amounts  of  35SO42- and  this  was  insensitive  to 
digestion by either chondroitin ABC lyase or heparitinase 
(Fig. 5). 
These results demonstrate that neither CD44H nor splice 
variants lacking the v3 exon are modified with glycosamino- 
glycans when expressed in the B lymphoma Namalwa. Even 
the presence of the vl0 exon which contains the partial GAG 
motif SLSG (Jackson et al., 1992) does not appear to signal 
GAG addition. Instead, glycosaminoglyean modification is 
specific to CD44 isoforms containing the v3 exon, presum- 
ably reflecting direct modification of the v3 insert itself. 
Proteoglycan-like  CD44 Isoforms on Epithelial Cells 
Are v3 Splice Variants 
To  determine  whether  the  GAG-modification  seen  with 
recombinant CD44 isoforms in Namalwa cells was also a 
feature of native CD44 isoforms in other cell types, we stud- 
ied the GAG modifications of v3-containing variants present 
in epithelial cells. Since these latter molecules have not yet 
been identified at the protein level we surveyed a panel of epi- 
thelial cell lines by surface '25I-iodination  and immunopre- 
cipitation using a newly isolated v3 exon-specific mAb 3G5 
(Fox  et  al.,  1994)  in  addition  to  the  pan-CD44  mAb 
F.10.44.2 (Dalchau et al.,  1980). As shown in Fig. 6 A, the 
v3-containing variants in each of the cell lines A431, Hotz, 
HT29,  HeLa,  MCF7,  and MCF10 constituted a  heteroge- 
neous group of molecules within the size range 110-250 kD 
representing  in  most  cases  a  major  proportion  of  total 
CD44. Interestingly, the variants present in Hotz and A431 
cells were similar  in  molecular mass  to the  recombinant 
CD44v3-~0 isoform  expressed  in  Namalwa  cells  and  dis- 
played the same GAG-induced smearing on SDS-PAGE (see 
Fig.  3). 
To determine the identity of the GAG chains in more de- 
tail,  CD44  isoforms biosynthetically labeled with 35SO42- 
were immunoprecipitated from A431  and  Hotz cells and 
digested with either chondroitin ABC lyase or heparitinase. 
The results of  these analyses (Fig. 6 B) showed that a discrete 
high molecular weight population of CIM4 molecules simi- 
lar if not identical in both cell lines was modified with hepa- 
ran sulphate. In contrast, no significant 35SO~2- labeling of 
CD44H or other lower molecular weight CD44 variants was 
detected in either Hotz cells or A431 ceils despite the fact 
that these CD44 variants were clearly detectable in surface 
~25I-labeling experiments (Fig. 6 A).  Furthermore, the ma- 
jority of the high molecular-weight heparan sulphate-mod- 
ified CIM4 could be immunoprecipitated with the otv3 mAb 
3G5 (Fig.  6  B) indicating that these v3-containing splice 
variants are the major GAG-modified isoforms of both A431 
and Hotz cells. Complete immunoprecipitation of heparan 
Figure 5. Recombinant human CD44v3.s-~0 expressed in Namalwa 
cells is modified with heparan sulphate. Namalwa cells expressing 
the recombinant CD44  isoforms shown were biosynthetically la- 
beled with Na235SO4 in parallel followed by immunoprecipitation 
with the pan CD44 mAb E10.44.2 and digestion with either chon- 
droitin ABC lyase (lanes 2, 5, and 8) or heparitinase (lanes 3, 6, 
and 9). Lanes 1, 4, and 7 contain undigested controls. The same 
number of cells (3.3 x  105) was processed in each case. Samples 
were analyzed on 7.5 % acrylamide SDS-PAGE  gels and visualized 
by autoradiography. The molecular  weight calibration  markers 
were the same as those shown in Fig. 3. 
sulphate-modified CD44 from Hotz and A431 with the oe¢3 
mAb 3G5 could not be achieved because of the low affinity 
of this antibody compared with E10.44.2 as assessed in sep- 
arate experiments using CD44v3-10 using both immunopre- 
cipitation and FACS analysis (not shown). 
Binding of C1M4 lsoforms to Immobilized Hyaluronan 
and Extracellular Matrix Proteins 
In view of  the fact that CD44H previously has been proposed 
to function as a receptor for hyaluronan (for review see Un- 
derhill, 1992) and the extraceUular matrix proteins fibronec- 
tin,  collagen, and laminin,  each of which contain binding 
sites  for  glycosaminoglycans  (Hardingham  and  Fosang, 
1992), we tested the binding of our panel of CD44 trans- 
fected Namalwa  cells to  extracellular matrix components 
coated on plastic tissue culture dishes. 
We first measured binding of the panel of CD44 trans- 
fected Namalwa cells to hyaluronan. As shown in Fig. 7, the 
level of specific binding (% transfected cells bound-% con- 
trol  Namalwa  cells  bound)  was  severalfold  higher  for 
CD44H  (24%  specific binding)  than for the alternatively 
spliced  CD44  isoforms  (CD44vs-10, 9%;  CDa4v7-10, 7%; 
CD44v3-10,  7%;  CD44v6-t0, 3%;  and  CD44v3.8-10, 3% 
specific binding, respectively) confirming earlier findings by 
another group (Stamenkovic et al.,  1991) who reported re- 
duced binding by CD44vs-~0 in similar experiments. Impor- 
tantly, the reduced hyaluronan binding that we observed in 
our experiments could not be explained by low levels of 
CIM4 expression in the vCD44 transfected cell lines. First, 
Jackson et al.  CD44v3  Variants Are Heparan  Sulphate  Proteoglycans  679 Figure 6. Epithelial cell CD44 
isoforms  containing  the  v3 
exon are modified with hepa- 
ran  sulphate.  Endogenous 
CD44  isoforms were  immu- 
noprecipitated  from  radiola- 
beled epithelial cell lines and 
analyzed on 7.5 % SDS-PAGE 
gels  either  without  further 
treatment  or  after  treatment 
with either Chondroitin ABC 
lyase or  Heparitinase as  de- 
scribed under  Materials and 
Methods. In A, each of the cell 
lines indicated was surface la- 
beled with Iodine-125 and im- 
munoprecipitated with either 
the pan CD44 mAb E10.44.2 
or the v3 specific mAb 3G5 as 
shown  followed  by  electro- 
phoresis  on  a  7.5%  SDS- 
PAGE  gel.  The  prominent 
band of 50 kD visible in the 
MCF7  samples  cross-reacts 
with non-specific Ig and does 
not  constitute  an  isoform  of 
CD44 (data not shown). In B, 
the cell lines Hotz and A431 
were  biosynthetically labeled 
with  35SO4 before  immuno- 
precipitation with  either  the 
pan  CD44  mAb  E10.44.2 
(lanes  1  and  5)  or  the  v3 
specific mAb 3G5  (all other 
lanes)  followed by  treatment 
with Chondroitin ABC lyase 
(lanes  3  and  7)  or  Hepa- 
ritinase (lanes  4  and  8)  and 
the  samples  electrophoresed 
on a 7.5%  SDS-PAGE gel. 
the  levels  of  surface  expression  were  measured  for  each 
vCD44 transfectant both 8  wk before and  11  mo after per- 
forming the assay depicted in Fig. 7 and were found to differ 
by no  more than  30%  from the  CD44H  expression levels 
(Fig. 2). Second, the binding assay has been repeated three 
further  times  yielding  similar  results  that  in  each  case 
showed  a  statistically  significant  difference  between  the 
hyaluronan-binding capacities of CD44H  and vCD44  (see 
legend to Fig.  7). 
Interestingly, none of the transfectants expressing vCD44 
could be induced to bind hyaluronan by treatment with either 
phorbol myristate acetate or with the CD44 mAb F.10.44.2 
(data not shown),  conditions reported previously to induce 
hyaluronan binding in other CD44 ÷v° adhesion-deficient cell 
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nan. Namalwa cells stably transfected with the recombinant human 
CD44 isoforms shown were labeled with 51Cr before incubation in 
plastic multiwell dishes coated with hyaluronan as described under 
Materials and Methods. Untransfected Namalwa cells (CON) were 
included as a control for CD44 independent binding. The level of 
non-specific background  adhesion  (measured  using wells coated 
with BSA or desialated fetuin) was the same for each transfectant 
and was equivalent to 4,400 cpm or 8.4 % binding in the experiment 
shown. Values shown are the mean +  SD of triplicate determina- 
tions of the number of cells bound per well, normalized for differ- 
ences  in 51Cr incorporation  by each transfectant.  Values for the 
percentage of  cells bound were calculated as described in Materials 
and  Methods.  The  differences  in  hyaluronan  binding  between 
CD44H and vCD44 were significant to a probability p < 0.01 both 
in the experiment shown and in each of  two similar experiments not 
shown, as calculated using a two-tailed Student's t test. 
lines (Lesley et al.,  1990; Hyman et al.,  1991; Lesley et al., 
1992;  Liao et al.,  1994).  These latter results provide firm 
evidence that the variably spliced inserts within the mem- 
brane-proximal domain of CD44  can regulate the  ligand- 
binding affinity of the NH2-terminal domain. 
We also compared binding of the vCD44 transfectants to 
fibronectin  and  laminin  in  four  independent  experiments 
using ligand immobilized in 96-well plastic microtitre dishes 
(data  not  shown).  In  two  experiments  both  the  GAG- 
modified  isoforms  CD44v3,8-~0 and  CD44v3-10 displayed 
significant binding  (p <  0.02,  Student's t test, n  =  5/6) to 
fibronectin compared with  CD44H  and  CD44vs-to  (actual 
values  CD44v3,s-~0/CD44H;  3599  +  1294/1471  +  371 
cpm, experiment 1 and 6690  +  2239/3454  +  660 cpm, ex- 
periment 2).  Moreover, in the case of fibronectin, binding 
could be partially blocked (46-73 %, n  =  5) by the addition 
of heparin,  chondroitin  sulphate,  soluble CD44v3.8-~0, or a 
40-kD  proteolytic  fragment of fibronectin  containing  the 
heparin-binding site (not shown). However in two other ex- 
periments, binding of the v3 isoforms to fibronectin was not 
significantly different from CD44H. Similar results were ob- 
tained when we measured the binding of CD44 to laminin 
(not shown).  Given the extent of variability in the data, we 
conclude  that  the  interaction  between  CD44  and  both 
fibronectin and laminin is probably of low affinity, although 
when detectable this interaction appears to involve CD44- 
associated glycosaminoglycan chains. 
Finally  none of the  CD44  isoforms tested bound to the 
GAGs chondroitin 4-sulphate, chondroitin 6-sulphate, hepa- 
ran  sulphate,  or  keratan  sulphate  immobilized on  plastic 
microtitre dishes (data not shown). 
Discussion 
The multiple isoforms of CD44 expressed in different tissues 
are now known to be generated by the differential splicing 
of one to ten alternative exons vl-vl0 that encode variable 
portions  of the  membrane-proximal extracellular  domain 
(for review see Lesley et al.,  1994). This process can in the- 
ory produce more than 1,000 different CD44 variants from 
a  single gene (Screaton et al.,  1992) representing a degree 
of molecular diversity exceeded only by the lymphocyte anti- 
gen receptors. In addition to primary structural differences, 
CD44 variants also differ in terms of glycosylation thought 
to arise from the addition of sugars to sites within both the 
invariant region of the extracellular domain encoded by con- 
stitutively spliced exons (Jalkanen et al.,  1988; Camp et al., 
1991; Lokeshwar and Bourguignon,  1991) and the variant re- 
gion encoded by the alternatively spliced exons vl-10 (Brown 
et al.,  1991;  Screaton et al.,  1993).  Our studies have been 
directed in particular towards characterizing CD44 variants 
modified with glycosaminoglycans, prompted by recent sug- 
gestions that these proteoglycan-like molecules may be im- 
portant in the cellular processes of motility and matrix in- 
vasion  (Faassen  et  al.,  1992,  1993).  Furthermore  the 
knowledge that other proteoglycans unrelated to CD44 may 
function as receptors for diverse ligands  including  growth 
factors, proteolytic enzymes, extracellular matrix proteins, 
and  pathogenic  viruses  (Ruoslahti  and  Yamaguchi,  1991; 
Kjellen and  Lindahl,  1991;  Frevert et al.,  1993;  Shieh  et 
al.,  1992)  led  us to  investigate whether  similar functions 
might be mediated by proteoglycan-like variants of the CD44 
protein. 
In this present paper and the accompanying manuscript 
(Bennett et al.,  1994),  we have described the cloning,  ex- 
pression,  and  characterization  of proteoglycan-like CD44 
isoforms together with an investigation into their potential 
binding of extracellular matrix proteins and growth factors. 
Proteoglycan-like Isoforms of Human CD44 Are 
Generated by Alternative Splicing of the v3 Exon 
Previous studies involving proteoglycan molecules from var- 
ious  sources  have  identified  the  consensus  motif  SGXG 
(where X represents any amino acid) as the optimal site for 
serine modification by Xylose-Gal-Gal, the core trisaccha- 
ride unit common to both heparan sulphate and chondroitin 
sulphate side chains (Bourdon et al.,  1987).  Although the 
membrane-proximal region of human CD44H contains four 
potential motifs for GAG modification, these are of the basic 
SG type (Bourdon et al., 1985) only. Nevertheless it has been 
assumed until now that one or more of these motifs constitute 
the sites modified with glycosaminoglycans in high molecu- 
lar weight proteoglycanlike isoforms.  However, the  recent 
identification and sequencing of the ten alternatively spliced 
exons of human CD44 revealed that the v3 exon contains the 
optimal SGSG consensus motif for GAG modification, in the 
context of a  17-residue  sequence FSGSGIDDDEDFISSTI 
which is fully conserved between mouse, human, and rat. A 
• second motif also occurs within the vl0 exon, although in 
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(Jackson et al.,  1992).  Hence the possibility existed that 
some proteoglycan-like CD44  isoforms might in  fact be 
generated by alternative splicing.  In the present study we 
tested this possibility by comparing the glycosylation  patterns 
of recombinant CD44H,  CD44v~0, CD44v8-~0, CD44v7-10, 
CD44v6-1o, CD44~3.s-10, and CD44v3-t0 cloned in the expres- 
sion vector pRcCMV CD44v~oBg  ~/Nar*" and stably transfected 
into the CD44 -re B lymphoma Namalwa. 
We found that the two isoforms CD44~3.8-~0 and CD44~3-~0 
which carry the v3 exon were indeed modified with gly- 
cosaminoglycans; both  chondroitin sulphate and heparan 
sulphate were identified by a combination of 3~SO4 biosyn- 
thetic labeling and enzymatic deglycosylation. In contrast, 
we  detected  little  if any  glycosaminoglyean attached  to 
any of the  isoforms containing the  vl0  exon,  (CD44v~0, 
CD44vs-~0, CD44vT-~0, and  CD44~6-10)  or  to  CD44H.  In- 
stead these isoforms incorporated only trace levels of 35SOg 
in  linkages  that  were  stable  to  both  chondroitinase and 
heparitinase digestion, indicative of either peptide sulpha- 
tion  or  N-linked  glycosylation with  sulphated  sugars  as 
reported previously (Brown et al.,  1991). Furthermore we 
found that the majority of the high molecular weight GAG- 
modified CD44 isoforms in two different human epithelial 
cell lines (the squamous cell lung carcinoma Hotz and the 
epidermoid carcinoma A431) also contained the v3 exon as 
demonstrated by biosynthetic labeling and immunoprecipi- 
tation with the CD44 exon-specific mAb 3G5. In common 
with the recombinant CD44 isoforms expressed in Namalwa 
cells, these v3-containing isoforrns  in epithelial cells were 
also modified with heparan sulphate. 
These results alone suggest that the majority if not all 
proteoglycan-like forms of CD44 are in fact splice variants 
containing the v3 exon. This conclusion is further supported 
by the recent finding that "epican; the major heparan sul- 
phate-modified CD44 isoform of human foreskin keratino- 
cytes, is a v3-10 splice variant (Kugelman et al.,  1992).  In 
addition, high molecular weight heparan sulphate-modified 
CD44 isoforms identified in both squamous cell lung carci- 
noma and human foreskin keratinocytes were also identified 
as  alternative  splice  variants  in  a  recent  detailed  study 
(Brown et al.,  1991). 
Clearly however, not all proteoglycan-like forms of CD44 
are generated by alternative splicing since it is clear that 
CD44H itself may be modified with glycosaminoglycans in 
some cell types. For example both CIM4H and CD44~8-t0 
may be modified with chondroitin sulphate when expressed 
in simian COS cells as soluble IgFc chimaeras (see accom- 
panying manuscript [Bennett et al.,  1994]).  Furthermore, 
chondroitin sulphate-modified CD44 isoforms of 180 kD in 
the HT1080 fibrosarcoma cell line (Brown et al., 1991; Ben- 
nett et al., 1994) may also represent CD44H, as might some 
components  of the  high  molecular  mass  (200-250  kD) 
CD44 expressed on human T and B lymphocytes (Jalkanen 
et al.,  1988; Jalkanen and Jalkanen,  1992). 
Hence covalent modification of CD44 variants with GAGs 
is probably regulated both by tissue-specific glycosylation 
and by alternative splicing. In epithelial cells and transfected 
Namalwa cells as shown here, CD44 molecules are modified 
with heparan and chondroitin sulphate and isoforms contain- 
ing the v3 exon appear to be the main targets for glycosyla- 
tion.  In HT1080  cells and peripheral blood lymphocytes, 
only chondroitin sulphate is added and CD44H is probably 
the major target for glycosylation. One possibility is that 
chondroitin sulphate chains are added in tissue-specific fash- 
ion to one or more of the "invariant  ~ glycosylation sites en- 
coded in exons 5,  16, or 17 (Fig. 1 B and [Goldstein et al., 
1989;  Stamenkovic et ai.,  1989])  while heparan sulphate 
chains are added preferentially to the SGSG glycosylation 
site encoded by the v3 exon. This type of site specificity has 
been demonstrated for the proteoglycan syndecan in which 
an SGSG motif carries heparan sulphate while SG motifs 
carry chondroitin sulphate (Kokenyesi and Bernfield, 1994). 
However, we cannot rule out the alternative explanation that 
one or more of the invariant GAG sites in CD44H or the 
SLSG motif in exon vl0 is cryptic and becomes exposed for 
modification with heparan sulphate only after insertion of 
the v3 exon. In either case splicing of the v3 exon clearly 
plays a potentially important role in regulating the expres- 
sion of GAG-modified CIM4 variants. 
The generation of  variant forms of  proteoglycan molecules 
by the mechanism of alternative RNA  splicing described 
here is relatively uncommon but is not unique to CD44. For 
example, differential RNA splicing is thought to generate 
variants of versican with extended GAG attachment domains 
expressed  during chondrogenesis in the developing chick 
limb bud (Shinomura et al., 1993). In addition, RNA splic- 
ing generates cell surface proteoglycan forms of receptor- 
type protein tyrosine phosphatase in mammalian CNS (Bar- 
nea et al., 1994) and proteoglycan-like forms of type XII and 
XIV collagens in connective tissue (Koch et al.,  1992).  In- 
sertion of the v3 exon in CD44 transcripts occurs predomi- 
nantly in cells of epithelial origin and as we have shown very 
recently by immunohistochemical staining, many epithelial 
tissues express large amounts of CD44v3 protein isoforms 
(Fox et al.,  1994).  Hence the physiological function(s) of 
proteoglycan-like CD44 splice variants might be primarily 
to regulate epithelial cell-cell or cell-substratum interac- 
tions. In this respect the proteoglycan-like forms of CD44 
share  similar properties  with the syndecans, an abundant 
family of cell surface proteoglycans involved in tissue orga- 
nization and morphogenesis (Bernfield et al.,  1992).  Like 
the CD44 v3-containing isoforms, syndecans may be mod- 
ified with either chondroitin sulphate or heparan sulphate 
and are also expressed predominantly on cells of epithelial 
origin.  In addition, both molecules contain single dibasic 
sites for trypsin-like cleavage close to the membrane anchor 
(or in the case of CD44 within the membrane-proximal vl0 
exon, [Dougherty et al., 1991]) that may give rise to soluble 
forms as a result of proteolysis (Bazil  and Horejsi,  1992). 
Finally, as demonstrated in the accompanying manuscript 
(Bennett et al.,  1994),  CD44  isoforms containing the v3 
exon bind the growth factors basic fibroblast growth factor 
and heparin-binding epidermal growth factor via covalently 
linked  heparan  sulphate  side  chains,  a  property  recently 
reported for a  cell surface heparan sulphate proteoglycan 
thought to be identical to the syndecans (Kiefer et al., 1990). 
Although normally absent from lymphocytes and mono- 
cytes, expression of CD44 isoforms can also be induced tran- 
siently on both cell types after antigenic stimulation in vivo 
(Arch et al., 1992) or after treatment with mitogenic agents 
or cytokines in vitro (Koopman et al., 1993; Mackay et al., 
1994).  It is tempting to speculate that the transient display 
of CD44 GAG chains on "activated" leucocytes might pro- 
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growth factors during the inflammatory response or during 
the early stages of an immune response. 
Alternative Splicing of  Exons v4-vlO  Generates CD44 
Molecules That Are Heavily O-Glycosylated 
As distinct from the glycosaminoglycan modifications dis- 
cussed above, all CD44 variants  also contained extensive 
sialylated O-glycan modifications resulting from insertion of 
the variably spliced exon units. These results obtained from 
detailed biochemical analyses provide further evidence that 
the  alternative  exons  constitute  a  mucin-like  domain  as 
predicted initially from their hydrophyllicity and from their 
high content of serine and threonine residues.  Mucin-like 
regions in other leukocyte cell surface glycoproteins such as 
leukosialin (CD43) and the hinge region of the T cell mole- 
cule CD8  have been observed to adopt extended rod-like 
conformations in EM (Cyster et al., 1991) and hydrodynamic 
studies  (Boursier et al.,  1993).  Indeed if the  membrane- 
proximal region within the CD44~3-~o isoform were to adopt 
the  same conformation as the 224 residue mucin-like ex- 
tracellular domain of CIM3 (length 45 nm under EM; Cyster 
et al., 1991), then the 340-amino acid v3-10 insert would in- 
crease the length of the extracellular domain by some 60 nm. 
Hence, a general function of the alternative exons of CIM4 
may be to serve as spacer arms or act as scaffolds for the 
covalent attachment of sugar chains and glycosaminoglycans 
at critical positions for interaction with ligands in the ex- 
tracellular medium. 
GAG-modified CD44 lsoforms Have Reduced A~nities 
for Hyaluronan 
Using the panel of vCD44-transfected Namalwa cells, we 
found  that  both  CD44v3-to and  CD44v3.8-1o displayed 
markedly reduced binding to hyaluronan, previously iden- 
tified as the major extracellular matrix ligand for CD44H. 
Similarly the binding affinity of CD44,8-~0, CD44v7-10,  and 
CD44v6-~o for hyaluronan was considerably lower than that 
of CD44H despite the fact that each transfectant expressed 
comparable levels of CD44 on the cell surface. Hence, the 
insertion of variably  spliced exons  within  the  membrane 
proximal domain of CD44 appears to alter the binding af- 
finity of the NH2-terminal ligand-binding domain.  Indeed 
even the insertion of the vl0 exon alone reduces hyaluronan 
binding (not shown). Our results both confirm and extend the 
original findings of Stamenkovic et al.  (1991) who demon- 
strated  reduced  binding  to  immobilized  hyaluronan  for 
Namalwa transfectants expressing the human epithelial vari- 
ant of CD44 (CD44vs-~o) in comparison to CD44H. The in- 
hibitory effect of the variably spliced exon units might in the- 
ory result either from conformational changes induced by the 
polypeptide portion of the inserts or from steric hindrance 
of the ligand-binding site by O-linked or N-linked sugars or 
by  sialic  acid.  Alternatively,  the  variably  spliced  inserts 
might disrupt protein-protein interactions necessary for the 
formation of high affinity hyaluronan-binding sites. 
Whereas the experiments with Namalwa cell transfectants 
described here illustrate a role for alternative splicing in the 
regulation of CD44 hyaluronan-binding affinity, several re- 
cent publications have demonstrated that hyaluronan binding 
in some cells may be regulated by changes in the so-called 
"activation" status of the CD44 molecule. This form of regu- 
lation has been best characterized in the mouse CD44  +re T 
cell  line  SAKRTLS which  does  not bind  hyaluronan but 
which can be induced to do so after treatment with phorbol 
ester or with mAbs that induce aggregation or conforma- 
tional alteration in the CD44 molecule (Hyman et al., 1991). 
Similar induction of hyaluronan-binding was reported in the 
human T  cell line Jurkat transfected with CD44H and the 
CD44vs-m0 isoform (Liao et al.,  1993).  However we have 
been  unable  to  demonstrate  inducible  binding  of CD44 
splice  variants  to hyaluronan  in  our panel  of transfected 
Namalwa cells using either phorbol ester or the "activating" 
antibody E10.44.2  (Liao et al.,  1994).  CD44 isoforms in 
some types of cell may therefore function as receptors for 
ligands other than hyaluronan. 
GAG-modified CD44 Isoforms and Adhesion to 
Extracellular Matrix 
A  number  of different proteoglycan molecules  including 
• decorin in bone tendon and skin, perlecan in basement mem- 
brane,  and the syndecans in epithelia have been shown to 
bind extracellular matrix via interactions between covalently 
linked glycosaminoglycan side chains and proteins such as 
fibronectin, laminin, and collagen that possess binding sites 
for heparan sulphate and chondroitin sulphate (Kjellen and 
Lindahl,  1991). In common with such proteoglycans, some 
forms of the CD44 molecule have also been shown to bind 
components of the extracellular matrix. Most notably, Jalka- 
nen and Jalkanen (1992) have reported that a minor 180-200- 
kD chondroitin sulphate-modified isoform solubilized from 
human lymphocytes binds to immobilized fibronectin, lami- 
nin, and type I collagen. In some experiments we also found 
that the chondroitin and heparan sulphate-modified isoforms 
CD44v3.8-1o and CD44v3-t0 bound significantly to fibronectin 
and laminin and that the  interaction with fibronectin was 
GAG dependent. However, since binding could not be repro- 
duced in all experiments we conclude that the interaction is 
of low affinity. 
Nevertheless it is tempting to speculate that the high mo- 
lecular weight fibronectin-binding CD44 species described 
by  Jalkanen  and  Jalkanen  (1992)  in  fact  constitute  v3- 
containing isoforms. It will be necessary to determine the 
equilibrium binding  affinities for fibronectin and  laminin 
using soluble CD44 isoforms in order to clarify this issue. 
In conclusion, we have demonstrated that proteoglycan- 
like forms of CD44 normally expressed in epithelial cells 
constitute alternatively spliced isoforms containing the v3 al- 
ternative exon and these are shown to have affinity for the 
extracellular matrix protein fibronectin. Together with the 
demonstration in the accompanying paper (Bennett et al., 
1994),  that proteoglycan forms of CD44  sequester GAG- 
binding growth factors, this identifies a new and potentially 
important role for the CD44 v3 exon in the regulation of cell 
growth and migration. However the biological function(s) of 
the other alternative exons v4 through vl0 remain to be eluci- 
dated. Hence it is likely that other ligands for vCD44 iso- 
forms exist and their identification represents one of the most 
important goals in future CD44 research. 
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